Prospective Clinical Trial to Evaluate the Safety and Effectiveness of the IOL

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

369 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-23

Study Completion Date

2020-03-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To establish the safety and effectiveness of the CT LUCIA 611P posterior chamber intraocular lens for the correction of aphakia following extracapsular cataract extraction via phacoemulsification in adult patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal

NCT06264232

Cataract Senile

COMPLETED NA

Evaluation of Safety and Performance Outcomes of Eyedeal IOL Implantation After Cataract Removal

NCT05776095

Lens Implantation, Intraocular

RECRUITING NA

One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction

NCT01230060

Aphakia Cataract

COMPLETED PHASE3

Artisan Aphakia Lens for the Correction of Aphakia (Secondary) in Adults

NCT01547429

Aphakia

SUSPENDED NA

IC-8 Apthera IOL New Enrollment Post Approval Study

NCT06060041

Cataract Presbyopia Posterior Capsule Opacification

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract Unilateral Aphakia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group

Group Type EXPERIMENTAL

IOL

Intervention Type DEVICE

Intraocular lens

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IOL

Intraocular lens

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female, age 22 years or older at the time of study enrollment.
2. Visually significant cataract in the study eye for which phacoemulsification cataract extraction and posterior chamber IOL implantation is indicated.
3. Projected postoperative BCDVA 0.20 logMAR or better in the study eye, as determined by Investigator's medical judgment.
4. Calculated spherical power targeted at emmetropia at distance in the study eye.
5. Calculated IOL power between +4.0 D and +34.0 D, inclusive, in the study eye.
6. If wearing rigid gas permeable (RGP) contact lens in the study eye, willingness to discontinue lens wear for ≥ 30 days prior to preoperative biometry.
7. Availability, willingness, and sufficient cognitive awareness to return for study-required visits and comply with examination procedures.
8. Willingness to sign the IRB-approved informed consent form (ICF) for study participation.

Exclusion Criteria

1. Mature cataract in the study eye that is likely to prolong surgical procedure and/or lead to intraoperative complications prior to attempted IOL implantation.
2. Planned cataract removal using a femtosecond laser.
3. Any visually significant intraocular media opacity other than cataract in the study eye (as determined by the investigator).
4. Significant refractive error (hyperopia/myopia) of axial or pathologic origin in the study eye that, in the judgment of the investigator, could confound outcomes.
5. Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal degeneration, or irregular astigmatism).
6. Any anterior segment pathology in the study eye that could significantly affect outcomes (e.g. chronic uveitis, iritis, aniridia, rubeosis iridis, clinically significant corneal or anterior membrane dystrophies, poor pupil dilation, etc.)
7. Any condition in the study eye that could affect IOL stability (e.g. pseudoexfoliation, zonular dialysis, evident zonular weakness or dehiscence, etc.).
8. History of severe dry eye in the study eye that, in the judgment of the investigator, would impair the ability to obtain reliable study measurements.
9. History of serious corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.) in either eye.
10. History of any clinically significant retinal pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy, amblyopia, strabismus, microphthalmos, aniridia, epiretinal membrane etc.) in the study eye that could alter or limit final postoperative visual prognosis.
11. History of cystoid macular edema in either eye.
12. History of uveitis in either eye.
13. History of intraocular or corneal surgery in the study eye.
14. Uncontrolled glaucoma in the study eye (per Investigator judgment).
15. Current ocular infection in the study eye.
16. Fellow eye BCDVA worse than 1.0 logMAR.
17. Presence of uncontrolled systemic disease that could increase operative risk (e.g., diabetes mellitus, active cancer treatment, mental illness, dementia, immunocompromised, connective tissue disease, clinically significant atopic disease, etc.).
18. Use of or history of use of systemic medications with significant ocular side effects or any medications that could confound the outcome or increase patient risk (e.g., steroids, Tamsulosin Hydrochloride \[Flomax\] or other medications including anticholinergics or alpha-adrenergic blocking agents with similar side effects \[e.g. small pupil/floppy iris syndrome\], anti-metabolites, etc.)
19. Participation in any other non-eye related drug or device clinical trial within 30 days prior to enrolling in this study and/or during study participation.
20. Participation in any eye-related drug or device clinical trial within 90 days prior to enrolling in this study and/or during the study participation.
21. Planned concomitant ocular procedure during cataract surgery (e.g., glaucoma surgery including implantation of MIGS, astigmatic correction surgery, penetrating keratoplasty \[PK\], laser-assisted in situ keratomileusis \[LASIK\], etc.)
22. Pregnant, lactating or, if able to bear children, unwilling to use medically acceptable birth control over the course of the study.
23. Unsuitable for study participation for any other reason, as determined by Investigator's clinical judgment (reason to be documented on eCRF).

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No